A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume 27, Issue 4, Pages 680-687
Publisher
Oxford University Press (OUP)
Online
2016-01-23
DOI
10.1093/annonc/mdw004
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial
- (2015) Calin Cainap et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Mapatumumab, a Fully Human Agonist Monoclonal Antibody to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 1 (TRAIL-R1), in Combination With Paclitaxel and Carboplatin in Patients With Advanced Non–Small-Cell Lung Cancer
- (2014) Joachim von Pawel et al. Clinical Lung Cancer
- Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial
- (2014) Masatoshi Kudo et al. HEPATOLOGY
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- World Medical Association Declaration of Helsinki
- (2013) JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
- (2013) Philip J. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
- (2013) Ann-Lii Cheng et al. JOURNAL OF CLINICAL ONCOLOGY
- Sorafenib Sensitizes Solid Tumors to Apo2L/TRAIL and Apo2L/TRAIL Receptor Agonist Antibodies by the Jak2-Stat3-Mcl1 Axis
- (2013) Junaid Abdulghani et al. PLoS One
- A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma
- (2010) A Younes et al. BRITISH JOURNAL OF CANCER
- Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer
- (2010) T Trarbach et al. BRITISH JOURNAL OF CANCER
- Expression, Cellular Distribution, and Prognostic Relevance of TRAIL Receptors in Hepatocellular Carcinoma
- (2010) L. Kriegl et al. CLINICAL CANCER RESEARCH
- Sorafenib Overcomes TRAIL Resistance of Hepatocellular Carcinoma Cells through the Inhibition of STAT3
- (2010) K.-F. Chen et al. CLINICAL CANCER RESEARCH
- Sorafenib Inhibits STAT3 Activation to Enhance TRAIL-Mediated Apoptosis in Human Pancreatic Cancer Cells
- (2010) S. Huang et al. MOLECULAR CANCER THERAPEUTICS
- Current Strategy for Staging and Treatment: The BCLC Update and Future Prospects
- (2010) Alejandro Forner et al. SEMINARS IN LIVER DISEASE
- Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
- (2010) Riccardo Lencioni et al. SEMINARS IN LIVER DISEASE
- Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study
- (2009) C. H. Mom et al. CLINICAL CANCER RESEARCH
- Altered regulation of extrinsic apoptosis pathway in HCV-infected HCC cells enhances susceptibility to mapatumumab-induced apoptosis
- (2009) Xiaozhen Zhang et al. HEPATOLOGY RESEARCH
- Mapatumumab, an Antibody Targeting TRAIL-R1, in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Malignancies: Results of a Phase I and Pharmacokinetic Study
- (2009) Stephen Leong et al. JOURNAL OF CLINICAL ONCOLOGY
- TRAIL-induced apoptosis of hepatocellular carcinoma cells isaugmented by targeted therapies
- (2009) Bruno Christian Koehler et al. WORLD JOURNAL OF GASTROENTEROLOGY
- A Phase 1 Study of Mapatumumab (Fully Human Monoclonal Antibody to TRAIL-R1) in Patients with Advanced Solid Malignancies
- (2008) S. J. Hotte et al. CLINICAL CANCER RESEARCH
- Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. JNCI-Journal of the National Cancer Institute
- Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer
- (2008) F. Anthony Greco et al. LUNG CANCER
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hepatocellular carcinoma: Epidemiology, risk factors and pathogenesis
- (2008) Asmaa Ibrahim Gomaa et al. WORLD JOURNAL OF GASTROENTEROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started